STANDARD TREATMENT WORKFLOW (STW)

Epilepsy

Jeyaraj Pandiyan¹, Manjari Tripathi², Salil Gupta³, Shefali Gulati⁴, Sylaja PN⁵, Vivek Nambiar⁶, Karamvir Goyal⁷, P K Misra⁸, Sapna Erat Sreedharan⁹

¹Christian Medical College and Hospital, Ludhiana; ²All India Institute of Medical Sciences, New Delhi; ³R & R Hospital, New Delhi; ⁴All India Institute of Medical Sciences, New Delhi; ⁵Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum; ⁶AIMS, Kochi; ⁷Ludhiana; ⁸Lucknow District Hospital; ⁹Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum

CORRESPONDING AUTHOR

Jeyaraj Pandiyan, Christian Medical College and Hospital, Ludhiana

Email: jeyarajpandian@hotmail.com

CITATION

Pandiyan J, Tripathi M, Gupta S, Gulati S, Sylaja PN, Nambiar V, Goyal K, Misra PK, Sreedharan SE. Epilepsy. Journal of the Epidemiology Foundation of India. 2024;2(1Suppl):S195-S196.

DOI: https://doi.org/10.56450/JEFI.2024.v2i1Suppl.098

This work is licensed under a Creative Commons Attribution 4.0 International License.

©The Author(s). 2024 Open Access

DISCLAIMER

This article/STW, was originally published by Indian Council of Medical Research (ICMR) under Standard Treatment Workflow. The reprinting of this article in Journal of the Epidemiology Foundation of India (JEFI) is done with the permission of ICMR. The content of this article is presented as it was published, with no modifications or alterations. The views and opinions expressed in the article are those of the authors and do not necessarily reflect the official policy or position of JEFI or its editorial board. This initiative of JEFI to reprint STW is to disseminate these workflows among Health Care Professionals for wider adoption and guiding path for Patient Care.



Standard Treatment Workflow (STW) for the Management of

EPILEPSY ICD 10 - G40




- ite Uns insult, anuibioutes, and metabolic causes)
 ororatory investigations: CBC, liver function tests, routine biochemistry,
 mogram, lipid profile, vit D levels, TFT (whichever feasible)
 iation of treatment:
 Treat the patient if patient has epilepsy (2 or more episodes of unprovoked





Standard Treatment Workflow (STW) for the Management of **EPILEPSY**

ICD 10 - G40



Episodes could be single with high risk of recurrence. Prolonged motor convulsion of > 5 mins with loss of consciousness - STATUS EPILEPTICUS (SE) - MEDICAL EMERGENCY

PRIMARY HEALTH CENTRE (MEDICAL OFFICER)

- Clinical diagnosis of epilepsy: detailed history from an eyewitness
 Differentiate between provoked seizures and epilepsy (provoked due to fever,
 acute CNS insult, antibiotics, and metabolic causes)
 Laboratory investigations: CBC, liver function tests, routine biochemistry,
 hemogram, lipid profile, vit D levels, TFT (whichever feasible)
 Initiation of treatment:
 Treat the patient if patient has epilepsy (2 or more episodes of unprovoked
- Treat the patient if patient has epilepsy (2 or more episodes of unprovoked seizures)
 Treat a single seizure if risk of recurrence is high as in patients with focal seizures abnormalEEG. neuroimaging
 Anti Epileptic Drug (AED broad spectrum, low dose, start low go slow, except status epilepticus)
 Emergency medical care of status epilepticus
 Treatment counselling: side effects/toxicities of drugs, red flags, importance of adherence, maintaining treatment diary
 Advice on prevention of seizures: regular medication, sleep 7-8 hrs, avoid excess TV/mobile/ photic stimulation, regular diet. lifestyle choices(avoid alcohol)
 Evaluate any possibility of superimposed non-epileptic seizure
 Training of MLP/ANM/ASHA on epilepsy
 For excessive alcohol use, refer to ANM/MLP where psychosocial interventions are carried out for substance use disorders
 Follow up visits for treatment monitoring & difficult patients under neurologist at STC centre
 Basic management of co-morbidities (behaviour, cognition, reproductive health,

- asic management of co-morbidities (behaviour, cognition, reproductive health, one health)
- bone health) Alert to signs of abuse and neglect Maintain upward referrals with paediatrician/physician at DH

- Redflag Signs Progressive problems, rapid appearance of new symptoms Recent injury
- ns appearing after
- symptoms appearing a alcohol binge Status epilepticus after stabilization

RED FLAG SIGNS

- Laboratory investigation
 CBC, liver function
 tests, antiepileptic drug
 levels, routine
 biochemistry,

AED- BROAD SPECTRUM (GENERALIZED SEIZURES) Sodium Valproate (avoid in women of child bearing age unless non responsive to other drugs)

Lamotrigine

Levetiracetam

Oxcarbazepine Phenobarbitone

Topiramate AED (focal seizures)

DOSE (MAINTENANCE: MG/D)

Starting dose :200mg TDS Maintenance Dose: 600-2400

Starting dose: 25mg HS (Lower dose with VPA) Maintenance Dose: 100-300

Starting dose: 250mg BD Maintenance Dose: 1000-3000

Starting dose: 25mg OD Maintenance Dose: 100-400

Starting dose: 100mg BD Maintenance dose: 400-1200

Starting dose: 150mg BD Maintenance dose: 600 to 1800 Starting dose: 30mg HS Maintenance dose: 60-180

Starting dose: 200mg HS Maintenance dose:200-400

ADVERSE EFFECTS

Anorexia, wt gain, nausea, vomiting, tremors, hair loss, PCOS, thrombocytopenia

Sedation, ataxia, dizziness, skin rash, SJS (lower risk with slow titration)

Somnolence, dizziness, cognitive slowing,

Sedation, somnolence, cognitive problems, weight loss, word finding difficulty, renal stones, seizure worsening

Sedation, dizziness, ataxia, skin rash, SJS, hyponatremia, seizure worsening in some situations

Sedation, dizziness, ataxia, headache hyponateremia, skin rash

Sedation, ataxia, depression, memory problems, hyperactivity in children, skin rash

Ataxia, sedation, gum hyperplasia, coarsening of facial features, hirsutism, memory problems, osteomalacia & bone loss, skin rash

IMPENDING SE

Can be used for generalized also

ESTABLISHED SE

REFRACTORY SE

N 30 MIN 60 MIN 2 IV drugs fail (Benzo + IV AED) FIRST ABCS TO BE DONE FROM WHEN YOU SEE PATIENT SIMULTANEOUSLY WITH MEDICATION Out of Hospital/home : Buccal/Intranasal IMDZ with acute repititive seizures/status (0.3-0.5 mg/kg)

EMERGENCY ROOM

IV Lorazepam up to 0.1 mg/kg @ 2mg/min

OR
IV Midazolam 0.1-0.2 mg/kg bolus or 0.05-0.5 mg/kg/hr in CIV
OR

IV Diazepam upto 0.25-0.4 mg/kg over 2-3 min

- Phenytoin @50 mg/min 20 mg/kg repeat
 plus 10 mg/kg if seizures do not stop in 15-20 min
 If seizures not controlled or contra indiction (CI) to PHT
 Intravenous Valproate 25-40 mg/kg @3-6 mg/kg/min

 If CI to above two; Phenobarbitone 20 mg/kg IV @ less than 5-60 mg/min but be
 prepared to Intubate and ventilate

Levetiracetam 20-30 mg/kg IV at 5 mg/kg/min (max 3g) or Levetiracetam 1500-3000 mg via NGT or Lacosamide 200-400 mg IV at 40-80 mg/min Topiramate 150-800 mg bid via NGT

ICU
IV Midazolam loading 0.2 mg/kg
OR CIV 0.05-0.5 mg/kg/hr
(can go up to 2 mg/kg/hr)
Taper gradually after seizure stops
(preferably as evidenced by EEG)

Thiopental 5-7 mg/kg IV bolus further 50 mg until seizures controlled 3-5 mg/kg/hr for only 48 hours

OR Propofol IV loading 2-5 mg/kg
CIV 1-15 MC/KC/HR
OR Pentobarbital IV upto 10 mg/kg
< 0.2-0.4 mg/kg/min CIV 0.5-2 mg/kg/h
OR Ketamine bolus 1.5 mg/kg
CIV 0.01-0.05 mg/kg/h max 10mg/kg/hr * to be
FEG Monitorine EEG Monitoring

Airway, blood pressure, temperature, intravenous access, electrocardiography, CBC, glucose, electrolytes, AED levels, ABG, oximetry, tox screen, central line If alcoholic-thiamine & glucose, if diabetic GLUCOTEST/blood sugar & glucose IV. MUST INFORM CONSULTANT ON CALL

★ KEEP A HIGH THRESHOLD FOR INVASIVE PROCEDURES

This STW has been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the treating physician. There will be no indemnity for direct or individence consequences. Kindly visit our web portal (stw./em.org.in) for more information.

© Indian Council of Medical Research and Department of Health Research, Ministry of Health & Family Welfare, Covernment of India.

© 2024 JEFI S196